Factors predictive of marked decrease in HDL-C by probucol treatment.
Probucol markedly reduces the LDL-C level in hyperlipidemic patients. However, it also reduces HDL-C which is believed to result in an anti-atherosclerotic effect. Many hyperlipidemic patients treated with Probucol show a marked reduction in the HDL-C level, and administration of the agent to these patients requires proper caution. In this study, factors useful for predicting the reduction in HDL-C were examined in order to be able to predict the problem before actual administration. Probucol (250-750 mg/day) was administered to 30 patients with type II hypercholesterolemia. Among them, 23 patients showed a decrease greater than 20% in the HDL-C level after administration. To evaluate the factors which permit identification of this group, linear descriminant function analysis was performed using 12 pre-administration lipid levels. The analysis indicated that the Apo A-I/HDL-C ratio before Probucol has the greatest predictive value (F = 17.8, P less than 0.01) of all the parameters, and that the HDL-C level is reduced by 20% or more by Probucol administration when this ratio is 5.3 or less.
Yashiro
A
A
Second Department of Internal Medicine, University of Occupational and Environmental Health Japan, School of Medicine, Kitakyushu.
Nakashima
Y
Y
Segawa
J
J
Kawashima
T
T
Kuroiwa
A
A
D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects*; D016002:Discriminant Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D014280:Triglycerides; D002784:Cholesterol; D011341:Probucol